COCRYSTAL PHARMA NEW O.N. (8CC) — Net Asset Quality Index
COCRYSTAL PHARMA NEW O.N. (8CC) has a Net Asset Quality Index of 65.2% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €9.71 Million minus total liabilities of €3.38 Million yields net assets of €6.33 Million. A higher index indicates a stronger, lower-leverage balance sheet. Also explore COCRYSTAL PHARMA NEW O.N. balance sheet assets for the complete picture of this company's asset base.
Quality Index
Net Assets
Total Assets
Total Liabilities
COCRYSTAL PHARMA NEW O.N. Net Asset Quality Index Over Time (2021–2025)
This chart shows how COCRYSTAL PHARMA NEW O.N.'s Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 65.2%, representing net assets of €6.33 Million against total assets of €9.71 Million EUR. See 8CC working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for COCRYSTAL PHARMA NEW O.N. (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for COCRYSTAL PHARMA NEW O.N. from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of COCRYSTAL PHARMA NEW O.N..
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 65.2% | €6.33 Million | €9.71 Million | €3.38 Million | ▼ -5.6 pp |
| 2024 | 70.8% | €9.52 Million | €13.46 Million | €3.93 Million | ▼ -13.6 pp |
| 2023 | 84.4% | €26.38 Million | €31.26 Million | €4.88 Million | ▼ -12.5 pp |
| 2022 | 96.9% | €39.57 Million | €40.84 Million | €1.27 Million | ▼ -0.8 pp |
| 2021 | 97.7% | €77.55 Million | €79.39 Million | €1.84 Million | — |